Immune Cell Stimulators: IDO
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02178722 | II | Epacadostat, Pembrolizumab | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037) | Epacadostat+pembrolizumab combination shows encouraging anti-tumor activity with acceptable safety ORR: 8% abs Jun 2017 |